Well-known examples include antibodies that target tumor expressing receptors for epidermal growth factor (EGF), called Herceptin, those that target HER-2 [2], and those that are directed against angiogenic, tumor blood vessel growth-promoting vascular endothelial growth factor (VEGF), known as Avastin [3]. This evidence concerns the gene ERBB2 and neoplasm.